(original) (raw)

TY - JOUR AU - Goede, V. AU - Coutelle, O. AU - Neuneier, J. AU - Reinacher-Schick, A. AU - Schnell, R. AU - Koslowsky, T C AU - Weihrauch, M R AU - Cremer, B. AU - Kashkar, H. AU - Odenthal, M. AU - Augustin, H G AU - Schmiegel, W. AU - Hallek, M. AU - Hacker, U T PY - 2010 DA - 2010/10/01 TI - Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy JO - British Journal of Cancer SP - 1407 EP - 1414 VL - 103 IS - 9 AB - The combination of chemotherapy with the vascular endothelial growth factor (VEGF) antibody bevacizumab is a standard of care in advanced colorectal cancer (CRC). However, biomarkers predicting outcome of bevacizumab-containing treatment are lacking. As angiopoietin-2 (Ang-2) is a key regulator of vascular remodelling in concert with VEGF, we investigated its role as a biomarker in metastatic CRC. SN - 1532-1827 UR - https://doi.org/10.1038/sj.bjc.6605925 DO - 10.1038/sj.bjc.6605925 ID - Goede2010 ER -